A Study Comparing CRx-102 Plus Disease-modifying Anti-rheumatic Drug (DMARD) Therapy to Placebo Plus DMARD Therapy in RA
Status:
Completed
Trial end date:
2006-11-01
Target enrollment:
Participant gender:
Summary
This study was a Multicenter, Randomized, Blinded Study Comparing the Effect of CRx-102 Plus
DMARD Therapy to that of Placebo Plus DMARD Therapy on Serum C Reactive Protein (CRP) and
Cytokines in Subjects with Rheumatoid Arthritis. This Phase II, 6-week blinded study was
planned for 60 subjects with moderate to severe rheumatoid arthritis (RA).